Elixiron Immunotherapeutics (hong Kong) Ltd.

This study is testing whether a new immune-targeting drug called EI-001 can help improve skin repigmentation in adults with non-segmental vitiligo. About 45 participants will be randomly assigned to receive either the drug or a placebo to compare results. The main goal is to see …